Dr Reddy's Laboratories (BSP:R1DY34) 6-Month Share Buyback Ratio : -0.05% (As of Dec. 2024 )

View and export this data going back to 2020. Start your Free Trial

What is Dr Reddy's Laboratories 6-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Dr Reddy's Laboratories's current 6-Month Share Buyback Ratio was -0.05%.

Competitive Comparison of Dr Reddy's Laboratories's 6-Month Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dr Reddy's Laboratories's 6-Month Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's 6-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Dr Reddy's Laboratories 6-Month Share Buyback Ratio Calculation

Dr Reddy's Laboratories's 6-Month Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

6-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Jun. 2024 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Jun. 2024 )
	=	(4996.362	-	4998.726)	/	4996.362
	=	-0.05%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr Reddy's Laboratories (BSP:R1DY34) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Dr Reddy's Laboratories 6-Month Share Buyback Ratio Related Terms

Dr Reddy's Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (BSP:R1DY34) » Definitions » 6-Month Share Buyback Ratio

Traded in Other Exchanges

RDY:USA DRREDDY:India 500124:India RDDA:Germany RDDA:Germany

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Dr Reddy's Laboratories Headlines

No Headlines